Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 85, Issue 10, 2000, Pages 3754-3761

  Colao, Annamaria ^a   Marzullo, Paolo ^a   Spiezia, Stefano ^b   Giaccio, Assunta ^a   Ferone, Diego ^a   Cerbone, Gaetana ^a   Di Sarno, Antonella ^a   Lombardi, Gaetano ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b S Maria degli Incurabili Hospital of Naples   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ACROMEGALY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; GROWTH HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; MALE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE SURGERY; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0033763467     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.85.10.3754     Document Type: Article

References (38)

1. The endocrinology and developmental biology of the prostate
2. Serum insulin-like growth factor-I levels and prostate cancer risk: Interpreting the evidence
3. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors
4. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
5. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study
6. Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines: LNCaP, DU145 and PC-3 cells
7. Growth factor involvement in progression of prostate cancer
8. The prostatic IGF system: New levels of complexity
9. Growth hormone and prostate cancer: Guilty by association?
10. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients
11. Insulin-like growth factor-I and -II in human benign prostatic hyperplasia: Relationship with binding proteins 2 and 3 and androgens
12. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor β1 on programmed cell death through a p53- and IGF-independent mechanism
13. Effect of growth hormone (GH) and insulin-like growth factor-1 on prostate diseases: An ultrasonographic and endocrine study in acromegaly. GH-deficiency and healthy subjects
14. Prostate hyperplasia: An unknown feature of acromegaly
15. Effect of growth hormone (GH) and/or testosterone deficiency on the prostate: An ultrasonographic and endocrine study in GH deficient adult patients
16. GH and PRL excess
17. New developments in the management of acromegaly. Should we achieve absolute biochemical cure?
18. Extensive experience: Acromegaly
19. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly
20. Power Doppler US: A potentially useful alternative to mean frequency-based Color Doppler US
21. Reproducibility and observer variability of transrectal ultrasound measurements of prostatic volume
22. The development of human benign prostatic hyperplasia with age
23. Acromegaly
24. Acromegaly
25. Serum insulin-like growth factor-I is not a useful marker of prostate cancer
26. The pathogenesis of benign prostatic hyperplasia
27. The endocrinology and developmental biology of the prostate
28. Insulin-like growth factor-I receptors in human hyperplastic prostate tissue: Characterization, tissue localization, and their modulation by chronic treatment with a gonadotropin-releasing hormone analog
29. Role of growth factors, steroid and peptide hormones in the regulation of human prostatic tumor growth
30. Prostatic involution in men taking finasteride is associated with elevated levels of insulin-like growth factor-binding proteins (IGFBPs)-2, -4, and -5
31. Evidence that insulin-like growth factor-I and growth hormone are required for prostate gland development
32. Normal histology of the prostate
33. Somatostatin receptors in human prostate and prostate cancer
34. Somatostatin receptor in prostate tissue and derived cell cultures, and the in vitro growth inhibitory, effect of BIM-23014 analog
35. Different expression of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer
36. Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells
37. The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma
38. Expression of somatostatin receptors in peritumoral veins of human tumors